<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461186</url>
  </required_header>
  <id_info>
    <org_study_id>BAKMAL1501</org_study_id>
    <nct_id>NCT02461186</nct_id>
  </id_info>
  <brief_title>Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar</brief_title>
  <official_title>An Open-label Randomized Trial to Assess the Therapeutic Efficacy of Arterolane-piperaquine Versus Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Eastern Myanmar, an Area of Emerging Artemisinin-resistant Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mahidol Oxford Tropical Medicine Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Medical Research, Lower Myanmar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emerging resistance to artemisinins and their partner drugs severely threatens the treatment&#xD;
      of falciparum malaria in Myanmar with artemisinin combination therapies. To inform drug&#xD;
      policy, it is crucial to evaluate alternative antimalarial treatments.&#xD;
&#xD;
      The investigators here propose a randomized clinical trial comparing parasite clearance&#xD;
      parameters and efficacy of 3 days arterolane-piperaquine with standard treatment with 3 days&#xD;
      dihydroartemisinin (DHA)-piperaquine in adult patients with uncomplicated falciparum malaria&#xD;
      in Myanmar stratified for the presence of &quot;K13&quot; mutation in the infecting parasite strains.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - To assess the parasite clearance half-life of arterolane-piperaquine compared to&#xD;
      DHA-piperaquine in patients with artemisinin resistant uncomplicated falciparum malaria,&#xD;
      defined by presence of the &quot;K13&quot; mutations in the infecting parasite strain.&#xD;
&#xD;
      Secondary Objectives :&#xD;
&#xD;
        -  To assess the therapeutic efficacy of arterolane-piperaquine and DHA-piperaquine for the&#xD;
           treatment of uncomplicated falciparum malaria or mixed infection (P.falciparum (PF) + a&#xD;
           non-falciparum species) at Day 42, stratified by presence of artemisinin resistance in&#xD;
           the infecting parasite strain.&#xD;
&#xD;
        -  To assess the frequency of adverse events and serious adverse events of&#xD;
           arterolane-piperaquine compared to DHA-piperaquine.&#xD;
&#xD;
        -  To assess other efficacy parameters related to parasite clearance and parasite cure rate&#xD;
           as well as the gametocyte carriage.&#xD;
&#xD;
        -  To obtain pharmacokinetic (PK) and pharmacokinetic/pharmacodynamics (PK/PD) data on&#xD;
           arterolane-piperaquine and DHA-piperaquine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Change of the study site due to the current political climate in Myanmar.&#xD;
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral blood parasite half-life</measure>
    <time_frame>2 years</time_frame>
    <description>Peripheral blood parasite half-life of the linear portion of the natural logarithm parasite clearance curve in patients with parasitaemia at inclusion &gt;10,000 parasites/µL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>42 day PCR corrected adequate clinical and parasitological response (ACPR)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Uncomplicated Falciparum Malaria</condition>
  <condition>Artemisinin-resistant</condition>
  <arm_group>
    <arm_group_label>Arterolane maleate-piperaquine phosphate (Synriam)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dihydroartemisinin-piperaquine phosphate (Duocotexin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arterolane maleate-piperaquine phosphate (Synriam)</intervention_name>
    <arm_group_label>Arterolane maleate-piperaquine phosphate (Synriam)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-piperaquine phosphate (Duocotexin)</intervention_name>
    <arm_group_label>Dihydroartemisinin-piperaquine phosphate (Duocotexin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged ≥ 18 year old&#xD;
&#xD;
          -  Symptomatic malaria infection, i.e. history of fever or presence of fever &gt;37.5°c&#xD;
             (tympanic) within the last 24 hours.&#xD;
&#xD;
          -  Microscopic confirmation of asexual stages of P.falciparum (may be mixed with&#xD;
             non-falciparum species) with a parasitaemia &gt;10,000 parasites/µL&#xD;
&#xD;
          -  Able to take oral medication&#xD;
&#xD;
          -  Willingness and ability of patients to comply with the study protocol for the duration&#xD;
             of the study&#xD;
&#xD;
          -  Written informed consent given to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation (urine test for β HCG to be performed on any woman of child&#xD;
             bearing age 18 to 45 year old)&#xD;
&#xD;
          -  P.falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells&#xD;
             (175,000/µL).&#xD;
&#xD;
          -  Signs or symptoms indicative of severe malaria:&#xD;
&#xD;
               -  Impaired consciousness&#xD;
&#xD;
               -  Severe anaemia (Hct&lt;15%)&#xD;
&#xD;
               -  Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria,&#xD;
                  bleeding from venipuncture sites&#xD;
&#xD;
               -  Respiratory distress&#xD;
&#xD;
               -  Severe jaundice&#xD;
&#xD;
          -  Have taken a full course DHA-piperaquine, artemether-lumefantrin or other antimalarial&#xD;
             treatment in the previous 42 days&#xD;
&#xD;
          -  Known hypersensitivity to artemisinins or to piperaquine - defined as history of&#xD;
             erythroderma/other severe cutaneous reaction or angioedema&#xD;
&#xD;
          -  History of splenectomy&#xD;
&#xD;
          -  History of taking medicinal products that are known to prolong the QTc interval,&#xD;
             including:&#xD;
&#xD;
               -  Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide,&#xD;
                  procainamide, quinidine, hydroquinidine, sotalol).&#xD;
&#xD;
               -  Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine,&#xD;
                  haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive agents.&#xD;
&#xD;
               -  Certain antimicrobial agents, including agents of the following classes:&#xD;
&#xD;
                    -  macrolides (e.g. erythromycin, clarithromycin),&#xD;
&#xD;
                    -  fluoroquinolones (e.g. moxifloxacin, sparfloxacin),&#xD;
&#xD;
                    -  imidazole and triazole antifungal agent,&#xD;
&#xD;
                    -  pentamidine and saquinavir.&#xD;
&#xD;
               -  The non-sedating antihistamines terfenadine, astemizole, mizolastine.&#xD;
&#xD;
               -  Other drugs: cisapride, droperidol, domperidone, bepridil, diphemanil, probucol,&#xD;
                  levomethadyl, methadone, vinca alkaloids, arsenic trioxide.&#xD;
&#xD;
          -  History of taking any drug which is known to be metabolised by the cytochrome enzyme&#xD;
             CYP2D6 including flecainide, metoprol, imipramine, amitriptyline, clomipramine.&#xD;
&#xD;
          -  Family history of sudden unexplained death, or personal or family history of&#xD;
             predisposing cardiac conditions for arrhythmia/QT prolongation (including congenital&#xD;
             long QT syndrome, arrhythmia, QTc interval greater than 450 milliseconds with either&#xD;
             Bazett or Fridericia correction).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arjen M Dondorp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol Oxfrod Tropical Medicine Research Unit</affiliation>
  </overall_official>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arterolane-piperaquine</keyword>
  <keyword>Dehydroartemisinin-piperaquine</keyword>
  <keyword>therapeutic efficacy</keyword>
  <keyword>Uncomplicated falciparum malaria</keyword>
  <keyword>Artemisinin-resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Artenimol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

